

Donor 1964

Genetic Testing Summary

Fairfax Cryobank recommends reviewing this genetic testing summary with your healthcare provider to determine suitability.

Last Updated: 05/24/22

Donor Reported Ancestry: Italian, Danish

Jewish Ancestry: No

Genetic Test*	Result	Comments/Donor's Residual
		Risk**

Chromosome analysis (karyotype)	Normal male karyotype	No evidence of clinically significant chromosome abnormalities
Hemoglobin evaluation	Normal hemoglobin fractionation and MCV/MCH results	Reduced risk to be a carrier for sickle cell anemia, beta thalassemia, alpha thalassemia trait (aa/ and a-/a-) and other hemoglobinopathies
Cystic Fibrosis (CF) carrier screening	Negative by genotyping for 97 mutations.	1/343

*No single test can screen for all genetic disorders. A negative screening result significantly reduces, but cannot eliminate, the risk for these conditions in a pregnancy.

**Donor residual risk is the chance the donor is still a carrier after testing negative.

	ð			
OTIFER DIACNOG	ICS INCORPORATED		PATIENT INFORMATION DONOR1964, ONL	Y
QUEST DIAGNOST	ICS INCORPORATED		DOB: GENDER: M	A
SPECIMEN INFORM	MATION			
SPECIMEN:	IF339721L		ID: 1964-060131	
REQUISITION	: 6824519			
LAB REF NO:				
COLLECTED:	01/31/2006	08:45		
RECEIVED:	02/01/2006	05:55		
REPORTED:	02/02/2006	07:57		

· · · ·

.

REPORT STATUS	Final	
ORDERING PHYS	ICIAN	
CLIENT INFORM	ATION	

FAIRFAX CRYOBANK

Age:

Test Name	In Range	Out of Range	Reference Range	Lab
HEMOGLOBINOPATHY EVALUATION				
HEMOGLOBINOPATHY INDICES				IG
RED BLOOD CELL COUNT	4.68		4.20-5.80 MILL/MCL	
HEMOGLOBIN	14.3		13.2-17.1 G/DL	
HEMATOCRIT	41.0		38.5-50.0 %	
MCV	87.6		80.0-100.0 FL	
MCH	30.6		27.0-33.0 PG	
RDW	12.1		11.0-15.0 %	
HEMOGLOBINOPATHY				
EVALUATION				IG
HEMOGLOBIN A1	97.7		>96.0 %	
HEMOGLOBIN F	<1.0		<2.0 %	
HEMOGLOBIN A2 (QUANT)	2.3		1.8-3.5 %	
INTERPRETATION	NORMAL PHE	ENOTYPE.		
CHOLESTEROL, TOTAL	167		<200 MG/DL	IG
AST	23		3-50 U/L	IG
ALT	15		3-60 U/L	IG
CBC (INCLUDES DIFF/PLT)				IG
WHITE BLOOD CELL COUNT	4.4		3.8-10.8 THOUS/MCL	19
RED BLOOD CELL COUNT	4.68		4.20-5.80 MILL/MCL	
HEMOGLOBIN	14.3		13.2-17.1 G/DL	
HEMATOCRIT	41.0		38.5-50.0 %	
MCV	87.6		80.0-100.0 FL	
MCH	30.6		27.0-33.0 PG	
MCHC	34,9		32.0-36.0 G/DL	
RDW	12.1		11.0-15.0 %	
PLATELET COUNT	167		140-400 THOUS/MCL	
ABSOLUTE NEUTROPHILS	2297		1500-7800 CELLS/MCL	
ABSOLUTE LYMPHOCYTES	1606		850-3900 CELLS/MCL	
ABSOLUTE MONOCYTES	356		200-950 CELLS/MCL	
ABSOLUTE EOSINOPHILS	123		15-500 CELLS/MCL	
ABSOLUTE BASOPHILS	18		0-200 CELLS/MCL	
NEUTROPHILS	52.2		00	
LYMPHOCYTES	36.5		8	
MONOCYTES EOSINOPHILS	8.1		*	
BASOPHILS	2.8			
PUQALUTIO	0.4		20	

DONOR1964, ONLY ~ IF339721L

213/06

	PATIENT INFORMATION DONOR1964, ONLY	REPORT STATUS Final
EST DIAGNOSTICS INCORPORATED		ORDERING PHYSICIAN
EPORTED: 02/02/2006 07:57	DOB: Age: GENDER: M ID: 1964-060131	
Test Name	In Range Out of Range	Reference Range La
ABO GROUP & RH TYPE ABO GROUP RH TYPE	A RH (D) NEGATIVE	IG

Performing Laboratory Information:

, ,

IG QUEST DIAGNOSTICS-IRVING 4770 REGENT BLVD. IRVING TX 75063

DONOR1964, ONLY - IF339721L



Cystic Fibrosis Mutation Analysis

Patient Name: Donor 1964. Referring Physician: Specimen #:

Patient ID:

DOB: Not Given Sex: M SSN: Date Collected: 01/31/2006 Date Received: 02/01/2006 Lab ID: Hospital ID: Specimen Type: **BLDPER**

Ethnicity: Caucasian

Indication: Carrier test / Gamete donor

RESULTS: Negative for the 97 mutations analyzed

INTERPRETATION

This individual's risk to be a carrier is reduced from 1/25 (4%) to 1/343 (0.3%), based on these results and a negative family history.

Client #:

Case #:

COMMENTS:

Mutation Detection Ra among Ethnic Groups		based on mutation frequencies congenital absence of the vas de	In patients affected with cystic fibrosis. Among individuals with an atypical or mild ferens, pancreatitis) detection rates may vary from those provided here.
Ethnicity	Carrier risk reduction when no family history	Detection rate	References
African American	1/65 to 1/338	81%	Genet in Med 3:168, 2001
Ashkenazi Jewish	1/26 to 1/834	97%	Am J Hum Genet 51:951, 1994
Asian		Not Provided	Insufficient data
Caucasian	1/25 to 1/343	93%	Genet in Med 3:168, 2001; Genet in Med 4:90, 2002
Hispanic	1/46 to 1/205	78%	Genet in Med 3:168, 2001; www.dhs.ca.gov/pcfh/gdb/html/PDE/CFTable1.html
Jewish, non-Ashkenazi		Varies by country of origin	Genet Testing 5:47, 2001, Genet Testing, 1:35, 1997
Other or Mixed Ethnicity		Not Provided	Detection rate not determined and varies with ethnicity

This interpretation is based on the clinical information provided and the current understanding of the molecular genetics of this condition. Although DNA-based testing is highly accurate, rare diagnostic errors may occur. Examples include misinterpretation because of genetic variants, blood transfusion, bone marrow transplantation, or erroneous representation of family relationships or contamination of a fetal sample with maternal cells.


METHOD

DNA is isolated from the sample and tested for the 97 CF mutations listed. Regions of the *CFTR* gene are amplified enzymatically and subjected to a solution-phase multiplex allele-specific primer extension with subsequent hybridization to a bead array and fluorescent detection. The assay discriminates between Δ F508 and the following polymorphisms: F508C, I506V and I507V. In some cases, specific allele identification requires enzymatic amplification followed by hybridization to

Under the direction of:

nne Toonbl

Lynne Rosenblum-Vos, Ph. D. Testing Performed At Genzyme Genetics 3400 Computer Drive Westborough, MA 01581 1-800-255-7367 Date: 02/07/2006



Fairfax Cryobank Genetics and IVF Institute 3015 Williams Drive Suite 110 Fairfax VA 22031

MUTATIONS ANALYZED				
ΔF311	3120+1G>A	712-1G>T	Q359K/T360K	S549N
∆F508	3120G>A	935delA	Q493X	S549R T>G
∆l507	3171delC	936deITA	Q552X	T338I
1078delT	3199del6	A455E	Q890X	V520F
1288insTA	3659delC	A559T	R1066C	W1089X
1677delTA	3667del4	C524X	R1158X	W1204X
1717-1G>A	3791delC	CFTRdele2,3	R1162X	W1282X
1812-1G>A	3849+10kbC>T	D1152H	R117C	Y1092X C>A
1898+1G>A	3876delA	E60X	R117H	Y1092X C>G
1898+5G>T	3905insT	E92X	R334W	Y122X
1949del84	394delTT	G178R	R347H	
2043delG	4016insT	G330X	R347P	
2055del9>A	405+1G>A	G480C	R352Q	
2105del13ins5	405+3A>C	G542X	R553X	
2108delA	406-1G>A	G551D	R560T	
2143delT	444delA	G85E	R709X	
2183delAA>G	457TAT>G	K710X	R75X	
2184delA	574delA	L206W	R764X	
2184insA	621+1G>T	M1101K	S1196X	
2307insA	663delT	N1303K	S1251N	
2789+5G>A	711+1G>T	P574H	S1255X	
2869insG	711+5G>A	Q1238X	S364P	

ſ

This test was developed and its performance characteristics determined by Genzyme Genetics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing.

Genzyme GENETICS		Chromoso	me Analysi
Patient Name: Donor #19 Referring Physician: Specimen #: 17065847 Patient ID: 17052029-8-B	Client #: 606452	Fairfax Cryobank	
SSN:	Date Collected: 02/14/2006 Date Received: 02/16/2006 Lab ID: 1964-060214 Hospital ID: Specimen Type: Peripheral Blood		
Indication: Gamete donor			
Metaphases Counted: Metaphases Analyzed:	20	Banding Technique:	GTW

Ζ,

INTERPRETATION:

This analysis shows no evidence of clinically significant numerical or structural chromosome abnormalities. The standard cytogenetic methodology utilized in this analysis does not routinely detect small rearrangements and low level mosaicism, and cannot detect microdeletions.

Signed:


Ati Hajiantour

Atieh Hajianpour, FACMG

Date: 02/24/2006

Page 1 of 1

Testing Performed At Genzyme Genetics 655 East Huntington Drive Monrovia, CA 91016 E.Robert Wassman M.D., Laboratory Director 806 265 1616



Specimen #: **17065847 8** Specimen Type: Peripheral Blood Patient Name: Donor #1964, Adult Reviewed By: AH1 Karyotype: 46,XY

Dept ID: B1 Date Received: 02/16/2006 Date Reviewed: 02/24/2006 Genzyme GENERAL genetics